Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Cipla Primes For US Momentum But Seretide Generic Is Slow In UK

Executive Summary

Cipla reported a strong second quarter, with management upbeat about building momentum in the US business with a “good mix” of differentiated launches. The ramp-up of the firm’s Seretide generic in the UK, though, appears slow.

You may also be interested in...

Cipla Signals US Launch Momentum, Commodity-Like Price Cycle

Cipla's US business appears set to gain momentum with a string of differentiated generic launches lined up and the firm's CEO shares key insights into how price peaks and troughs could potentially play out in the world's largest pharmaceutical market.

Cipla, Sandoz Gearing For Seretide Challenge In Australia?

The Australian respiratory market seems set for a potential spurt in activity. Cipla and Sandoz appear to be gearing to take their respective competing versions of GlaxoSmithKline’s Seretide to Australia, piling up pressure on the UK multinational’s therapy there.

Christmas Cheer For Cipla’s Seretide Equivalent In The UK

Cipla's generic version of Seretide has finally received regulatory approval in the UK, bringing much needed relief to investors and opening up more competition for GlaxoSmithKline on its home turf.


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts